Dr Iris Good

Chair, Imperial College Innovation Fund

Iris is a scientist-entrepreneur and investor, specialising in commercialisation of healthcare technologies in international markets for over 20 years, focusing on the Indian market. Iris chairs Good Relations India, the Imperial College Enterprise Seed Fund, the London business School Health Tech Challenge, a member of the investment committee of Cambridge University Seed Fund and a trustee of Weizmann-UK Board. She has recently been appointed Global Chair Medical Innovation of the G-100 eminent club of top 100 powerful global women leaders with a vision to impact the future.

Soon after completion of her Ph.D. in Biochemistry from the Weizmann Institute of Science, followed by two post docs (molecular biology and brain research), Iris coestablished UltraShape and developed the first FDA-approved and commercially-used non-invasive aesthetic ultrasound procedure. The company was acquired by Syneron Medical Ltd ($12M). She then led the business development of MetaCure, a minimally invasive diabetic pace-maker, which she took to India, setting up pan-India clinical-trials and commercial operations. She founded I-Connections, an India market-entry firm focusing on cutting edge healthcare technologies, establishing strategic partnerships and commercial expansions. I-Connections later merged with Good Relations India, a 34-years old award-winning Strategic PR & Market Entry consultancy with offices in India and London, providing full market-entry strategy and execution to international corporates in India, becoming its chair in 2008. Good Relations India has advised leading clients such as Apple, Barclays, Bloomberg, Cartier, CNBC, Etihad, The UN and Virgin Atlantic together hundreds of start-ups. The company brought Marks & Spencer to India and created their JV with Reliance Industries, Sun Life Insurance with Birla Group, Scottish & Newcastle with Kingfisher and many others. 

Iris has served on the boards of Sight Diagnostics, Step of Mind and Tikal Networks (Israel) on the advisory board of Trapezia Capital and Puridify Ltd and on the main board of Accloud and Touchlight Genetics (UK).

She has been active mentor/judge/investor in London Business School, Judge Business School, Oxford Foundry and Imperial College. She has been a member of the Cambridge Seed Fund investment committee since 2018 and has chaired the Imperials College Seed Fund since 2020 and has been a trustee of Weizmann-UK since December 2021.

panel: 10:30 – 11:15

Reimagining Healthcare by Leveraging the Power of Technology and Innovation

Health Tech is a global powerhouse for investors and offers the opportunity to create long-term change to our healthcare system and the ways we engage with patient care from prevention through diagnoses and treatment. This panel will explore the why investing in health tech is so vital and what makes the UK a hotbed for innovation and leading competitor on the global stage. Dialling in on the trends turning heads and opportunities emerging, our experts will pull back the curtain on why the digital health market is one of the most lucrative in the world.